Depression in Patients With Cancer

McDaniel, J. Stephen; Musselman, Dominique L.; Porter, Maryfrances R.; Reed, Deborah A.; Nemeroff, Charles B.

doi:10.1001/archpsyc.1995.03950140007002

Cited by 473 publications

(87 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is similar to that found among cancer patients in remission (Carroll et al, 1993) and differs from the high prevalence of depression among cancer patients with active or advanced disease (Carroll et al, 1993;McDaniel et al, 1995). Among these, the high prevalence of depression may be linked to losses, either actual such as loss of function or anticipated such as death.…”

Section: Discussionsupporting

confidence: 78%

Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors

Loge

Abrahamsen²,

Ekeberg³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary To assess the levels of psychological distress and identify predictors of anxiety/depression caseness after cancer cure, a national population of 557 Hodgkin's disease (HD) survivors was surveyed. The respondents [204 women, 255 men, mean age 44 years (SD = 12)] returned a mailed questionnaire including The Hospital Anxiety and Depression Scale (HADS). Disease and treatment variables were based on the hospital records. A total of 27% had caseness scores (anxiety, 14.5%; depression, 4%; anxiety and depression, 8.5%). In a multiple logistic regression analysis, anxiety caseness was predicted by low educational status [OR (odds ratio) = 2.07, 95% Cl = 1.02-4.22], observational period 7 years or longer (7-10 years: OR = 3.07, 95% Cl = 1.26-7.47), combined irradiation and chemotherapy treatment (OR = 2.77, 95% Cl = 1.17-6.54) and psychiatric symptoms before HD (OR = 2.55, 95% Cl = 1.40-4.65) or during treatment (OR = 3.51, 95% Cl = 2.08-5.90). Depression caseness was predicted by age (OR = 1.03, 95% Cl = 1.00-1.06) and psychiatric symptoms before HD (OR = 5.1, 95% Cl = 2.55-10.31) Anxiety cases are more prevalent than in the general Norwegian population, and were found to be most common 7-10 years after treatment. The most intensive treatment was associated with increased risk for anxiety caseness. The subjects experienced distress during treatment precedes difficulties in long-term adjustment. Focusing on these predictors during treatment and follow-up controls may improve long-term outcome.

show abstract

Section: Discussionsupporting

confidence: 78%

Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors

Loge

Abrahamsen²,

Ekeberg³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The clinical challenge is to separate symptoms of a major depressive disorder which might encompass fatigue, insomnia and appetite loss from symptoms which are directly attributable to the cancer and/or its treatment, in order to make an accurate diagnosis of depression. 44 A recent study showed that physicians tended to underestimate the level of depressive symptoms in patients who were moderately to severely depressed. 45 An important question in this context is related to what are clinically significant changes.…”

Section: Discussionmentioning

confidence: 99%

The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation

Hjermstad

Loge

Evensen³

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Psychological distress is frequently reported in transplant survivors. We prospectively assessed anxiety and depression before transplant, in the isolation period and during a follow-up period of 1 year. The Hospital Anxiety and Depression Scale (HADS) was administered to 131 cancer patients treated with high-dose chemotherapy followed by allogeneic (SCT) or autologous (ASCT) stem cell transplantation, and a concurrent group of 123 lymphoma patients receiving standard chemotherapy (CT) who served as a reference group. Relatively low levels of anxiety and depression were found. The level of anxiety slightly declined from baseline during follow-up (mean scores SCT: from 5.3 to 3.6, CT: from 6.0 to 4.2) or remained fairly stable (ASCT: from 5.4 to 4.8). The level of depression peaked when the transplant patients were in protective isolation or shortly thereafter (SCT: 6.1, ASCT: 6.4), but stabilized at baseline levels after 4 months. The highest level of depression in the CT group was reported 4 months after start of chemotherapy (3.4). Elevated levels of anxiety and depression at baseline predicted more anxiety and depression at the later assessments (P values Ͻ0.0001). The ASCT group had higher levels of anxiety after 1 year (mean 4.8) than those found in the other two groups (SCT: 3.6, CT: 4.2), although they were not statistically significant. This study revealed lower than expected levels of anxiety and depression after intensive chemotherapy followed by SCT or ASCT. There was a decline in psychological distress during the 1-year follow-up period. Keywords: anxiety; depression; HADS; high-dose chemotherapy; prospective study Allogeneic (SCT) and autologous (ASCT) stem cell transplantation subsequent to high-dose chemotherapy (HDC) produces significant physical morbidity. 1,2 Most patients who undergo high-dose chemotherapy are young, and with increasing numbers of long-term survivors, prospective Correspondence: MJ Hjermstad, Department of Oncology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway Received 18 December 1998; accepted 15 July 1999 data on the prevalence and severity of psychological morbidity are important. In order to identify patients with symptoms of anxiety and depression in the early stages of disease and treatment, who might be at risk of psychological maladjustment after such intensive treatment, it is important to raise the awareness of signs of psychological distress in clinical oncology. A routine-based incorporation of assessment of anxiety and depression might be helpful.Previous studies which have used questionnaires such as the Profile of Moods State (POMS) or the Brief Symptom Inventory (BSI) for the evaluation of anxiety and depression, have shown that psychological distress is frequently reported by SCT and ASCT patients. The percentages of patients with these problems vary from 14% to 41%, depending on the study design, types of measures, and time of assessment relative to diagnoses and treatment. [3][4][5][6][7][8][9] When data from transplant patients ha...

show abstract

“…19 In our study we found that frequency of MDD was 40% which was consistent with previous studies. 1,[5][6][7][8][9][10][11][12][13] In comparison to normal population, higher rates of depression was found in this study because patients were chosen from oncology outpatient department of tertiary care hospital which is the highest source of patients with oral cancer. Among 28 patients of MDD, 19 patients (48.72%) were from advanced stage of cancer and 20 patients (71.42%) were labourer.…”

Section: Discussionmentioning

confidence: 75%

“…2 The incidence of depression in HNC patients ranges between 15% and 50%. [3][4][5][6][7][8][9][10][11] Important issue in HNC is depression: major depressive disorder (MDD) has been reported in up to 40% of patients with HNC, typically within the first 3 months of diagnosis. 12 The incidence of HNC is relatively low in developed countries and highest in South East Asia.…”

Section: Introductionmentioning

confidence: 99%

A study of major depressive disorder and quality of life in patients with oral cancer

Kantak

Vala

Panchal

2016

Int J Community Med Public Health

View full text Add to dashboard Cite

Depression in Patients With Cancer

Cited by 473 publications

References 132 publications

Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors

Psychological distress after cancer cure: a survey of 459 Hodgkin's disease survivors

The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation

A study of major depressive disorder and quality of life in patients with oral cancer

Contact Info

Product

Resources

About